Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Questions CV Events, Small Database Heading Into Aclidinium Bromide Advisory Committee

This article was originally published in The Pink Sheet Daily

You may also be interested in...



Tudorza’s Delivery System Key To Positioning For COPD Maintenance

Forest Laboratories’ sales representatives will combine marketing for aclidinium, which FDA approved July 24, with their education efforts for Daliresp for COPD exacerbations.

Forest Tudorza Pressair Approval For COPD Includes Post-marketing CV Safety Study

The twice-daily aclidinium, a long-acting antimuscarinic agent, should be available to wholesalers in the fourth quarter.

Aclidinium Bromide Gains Reluctant Advisory Committee Recommendation

Pulmonary-Allergy Drugs Advisory Committee members say post-marketing study is necessary, and Forest has already made a preliminary proposal.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS073781

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel